Anthracycline-related cardiotoxicity: Risk factors and therapeutic options in childhood cancers

  • Puma N
  • Ruggiero A
  • Ridola V
 et al. 
  • 2

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Anthracyclines play an important role in chemotherapeutic regimens for a wide spectrum of childhood tumors, but they can cause cytotoxic damage to cardiac cells, especially in combination with radiotherapy. Furthermore, cardiotoxicity increases with the cumulative dose and may lead to congestive heart failure and cardiomyopathy. Other factors, including age, pre-existing cardiac disease, length of follow-up, gender, route of administration, concomitant exposure to some chemotherapeutic drugs, trisomy 21 and black race, play a role in increasing the risk of cardiac dysfunction. The prevention of anthracycline-induced cardiotoxicity is mandatory as children are expected to survive for decades after being cured of their cancer. The purpose of this work is to point out the major risk factors of cardiotoxicity in children and to summarize some strategies to limit or prevent this complication and to treat the development of acute heart failure.

Author-supplied keywords

  • Acute heart failure
  • Anthracycline
  • Cardiotoxicity
  • Childhood cancer
  • Prevention
  • Risk factors

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • N. Puma

  • A. Ruggiero

  • V. Ridola

  • P. Maurizi

  • I. Lazzareschi

  • G. Attinà

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free